Notably, impaired AMPK activity in type 2 diabetes mellitus (T2DM) patients contributes to defective glucose uptake and fatty acid oxidation, resulting in hyperglycemia [1], positioning AMPK activation as a promising therapeutic strategy for T2DM via mitochondrial function improvement. This evidence concerns the gene PRKAA1 and type 2 diabetes mellitus.